FIRST AIRED: December 19, 2018

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!

We've got more news

Get our editor’s daily email summary of what’s going on in the world.

US Edition
Intl. Edition
Replay Program
More Info

COMING UP:Share Opener Variant 1



>> From Advil painkillers to Sensodyne toothpaste, a new giant is in the making in consumer health products. GlaxoSmithKline striking a deal with US rival Pfizer. The two will put their consumer health goods into a joint venture. With 7% of the global market, it would dwarf rivals like Johnson & Johnson.
The deal is all part of a big rethink by GSK boss Emma Walmsley, who took over last year. It will also see the British firm's prescription medicine and vaccines split into a standalone firm. And the move comes as a shock, Walmsley had previously played down the idea of breaking up the group.
Now GSK will be in the driving seat in the new venture, with a stake of almost 70%. For Pfizer, the deal ends a long headache. It has tried and failed to sell its consumer products unit. Now both companies promise big efficiency gains from the tie up, over $600 million a year.
Investors seem to buy it. GSK shares jumping 7% after the news broke.